

Contents

1	Introduction	1
1.1	Background	1
1.2	Introduction of Ibuprofen for Non-Prescription (OTC) Use	2
1.3	Experience at Prescription Level Dosage	3
1.4	Scope and Objectives	4
2	Biodisposition in Relation to Actions	5
2.1	Key Aspects of the Pharmacokinetics and Biodisposition of Ibuprofen	5
2.1.1	Impact of Variability in Pharmacokinetics	11
2.2	Plasma/Serum Concentrations Relevant to Onset of Analgesia	13
2.2.1	Dental Pain Model	16
2.2.2	Induced Pain Models	20
2.2.3	Applicability to Other Acute Pain States	25
2.3	Antipyresis	26
2.4	Therapeutically-Relevant Concentrations in Rheumatic Diseases	27
2.4.1	Plasma/Serum Levels in Arthritic Diseases	28
2.4.2	Accumulation in Synovial Fluids	30
2.4.3	Rectal Administration in Adults and Children	33
2.5	Pharmacokinetics in Children	37
2.5.1	Juvenile Idiopathic (Rheumatoid) Arthritis	40
2.5.2	Cystic Fibrosis	40
2.5.3	Patent Ductus Arteriosus	42
3	Mechanisms of Inflammation and Sites of Action of NSAIDs	43
3.1	Pathways of Inflammation	43
3.2	Link of Pharmacokinetics to Pharmacodynamics	45
3.3	Relation of Analgesic Effects to COX-1 and COX-2 Inhibition	49

3.4	Multiple Modes of Anti-inflammatory Activities	50
3.4.1	Pain Control Pathways	52
3.4.2	Antipyretic Activity	56
4	Clinical Efficacy	59
4.1	Dental Pain	59
4.2	Pain Relief at OTC Dosages	65
4.3	Treatment of Pain in Osteoarthritis and Related Conditions	68
4.4	Paediatric Uses	70
4.4.1	Acute Fever in Children	70
4.4.2	Juvenile Idiopathic (Rheumatoid) Arthritis	75
5	Drug Derivatives and Formulations	77
5.1	Dexibuprofen	77
5.2	Combinations with Caffeine	79
5.3	Ibuprofen–Codeine Combinations	81
5.4	Ibuprofen–Paracetamol Combination	83
5.5	Amino Acid and Salt Formulations	87
5.6	Topical Formulations	88
6	General Safety Profile	91
6.1	Introduction	91
6.2	Pharmacokinetic Aspects of Importance in the Safety of Ibuprofen	91
6.3	Pharmacokinetic Variations	94
6.4	Pharmacokinetics in Oriental Compared with Caucasian Populations	97
6.5	Influence of Disease States on PK of Ibuprofen	101
6.6	ADRs and Safety in Prescription-Level Doses	102
6.7	Epidemiological Studies	102
6.8	Outcomes from Large-scale Clinical Trials	104
6.9	Adverse Events Attributed to Ibuprofen at Non-prescription (OTC) Dosages	107
6.10	ADR Risks in Oriental Populations	113
6.11	Potential Concerns with Chinese Traditional and Herbal Medicines	116
6.12	Adverse Events and Safety in Paediatric Populations	119
7	Gastro-Intestinal Toxicity	123
7.1	Epidemiological Studies	125
7.2	GI Risks in Coxib Studies at Prescription Doses	130
7.3	GI Symptomatic Adverse Reactions	134
7.4	GI Events at OTC Dosages	134
7.5	GI Safety in Paediatric Populations	135
7.6	Reducing GI Risks	136

8 Cardiovascular Safety	141
8.1 Disease-related Issues	141
8.2 Heightened Concerns from the Coxib Studies	142
8.3 Epidemiological Studies	143
8.4 Recent Clinical Trials and Meta-Analyses	152
8.4.1 Individual Trials	155
8.5 Interaction of Ibuprofen with the Anti-platelet Effects of Aspirin	157
8.6 Effects in Hypertension	161
8.7 Congestive Heart Failure and Cardio-Renal Effects	162
8.8 Balancing CV and GI Risks of NSAIDs	162
9 Renal Toxicity	163
10 Hepatic Toxicity	165
11 Other Adverse Reactions	169
11.1 Hypersensitivity Reactions and Asthma	169
11.2 Cutaneous Reactions	171
11.3 Risk of Fractures	172
12 Global Assessment of Adverse Reactions and Human Toxicology	175
12.1 Initial Basis for Approval for OTC Sale in UK and USA	175
12.2 Experience in the UK	176
12.3 Cases of Poisoning in UK	179
12.4 Limitations on Analgesic Pack Sizes in UK	180
12.5 Concerns About Misuse of Analgesics in USA	180
13 Overall Assessment	183
13.1 Spontaneous ADRs and Toxicity	183
13.2 Benefit/Risk Analysis	185
13.3 Assessment of Risks and Procedures for Their Reduction	185
13.4 Examples of Advice for Ibuprofen Packages and PILs	187
14 Summary	189
References	191
Index	231